Literature DB >> 9584293

Comparison of the effects of AV nodal ablation versus AV nodal modification in patients with congestive heart failure and uncontrolled atrial fibrillation.

N Twidale1, T McDonald, K Nave, A Seal.   

Abstract

Radiofrequency (RF) catheter ablation of the atrioventricular node (AVN) and implantation of a ventricular pacemaker can improve cardiac performance in patients with congestive heart failure (CHF) and uncontrolled atrial fibrillation (AF). Alternatively, RF catheter modification of the AVN has been proposed to slow ventricular response during AF without requirement for permanent pacing. Among 44 consecutive patients (mean age 69.7 +/- 10.2 years) with drug resistant chronic AF, 22 (group I) had AVN ablation with permanent ventricular pacemaker implantation, while 22 patients had attempted AVN modification. Complete AV block was obtained in all group I patients while only seven (32%) AVN modification patients (group II) had permanent slowing of ventricular rate. Among patients in group I, mean left ventricular ejection fraction (EF) increased from 32.2% +/- 8.8% before ablation to 41.9% +/- 14.6% 4-weeks postablation (P < 0.01); exercise tolerance time (ETT) increased from 2.9 +/- 2.2 minutes to 4.5 +/- 2.9 minutes (P < 0.01); and quality-of-life score decreased from 66.1 +/- 22.6 to 36.9 +/- 17.1 (P < 0.01). By comparison, there was only a small increase in ETT in the seven successful group II patients (2.4 +/- 1.8 minutes to 3.0 +/- 1.9 minutes; P < 0.05) and there was no significant change in EF or quality-of-life. While AVN ablation can occasionally have transient adverse effects, it is more effective than AVN modification for improving cardiac performance in selected patients with CHF and AF.

Entities:  

Mesh:

Year:  1998        PMID: 9584293     DOI: 10.1111/j.1540-8159.1998.tb00119.x

Source DB:  PubMed          Journal:  Pacing Clin Electrophysiol        ISSN: 0147-8389            Impact factor:   1.976


  9 in total

Review 1.  The AFFIRM trial: main trial and substudies-what can We expect?

Authors:  D G Wyse
Journal:  J Interv Card Electrophysiol       Date:  2000-01       Impact factor: 1.900

Review 2.  Atrioventricular junction ablation and pacemaker implantation for heart failure associated with atrial fibrillation: potential issues and therapies in the setting of acute heart failure syndrome.

Authors:  Jason C Rubenstein; James A Roth
Journal:  Heart Fail Rev       Date:  2011-09       Impact factor: 4.214

Review 3.  Catheter-ablative techniques for the treatment of atrial fibrillation.

Authors:  P G Guerra; M D Lesh
Journal:  Curr Cardiol Rep       Date:  1999-07       Impact factor: 2.931

Review 4.  The state of patient-reported outcomes in atrial fibrillation : a review of current measures.

Authors:  Karin Coyne; Mary Kay Margolis; Susan Grandy; Peter Zimetbaum
Journal:  Pharmacoeconomics       Date:  2005       Impact factor: 4.981

5.  Atrioventricular Nodal Catheter Ablation in Atrial Fibrillation Complicating Congestive Heart Failure.

Authors:  Osmar Antonio Centurión; Karina Elizabeth Scavenius; Laura B García; Luis Miño; Judith Torales; Orlando Sequeira
Journal:  J Atr Fibrillation       Date:  2018-06-30

Review 6.  Disease-specific health-related quality of life questionnaires for heart failure: a systematic review with meta-analyses.

Authors:  Olatz Garin; Montse Ferrer; Angels Pont; Montserrat Rué; Anna Kotzeva; Ingela Wiklund; Eric Van Ganse; Jordi Alonso
Journal:  Qual Life Res       Date:  2008-12-04       Impact factor: 4.147

Review 7.  Some recent randomized clinical trials in the management of atrial fibrillation.

Authors:  D George Wyse
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

Review 8.  New approaches to atrial fibrillation management: a critical review of a rapidly evolving field.

Authors:  Stanley Nattel; Paul Khairy; Denis Roy; Bernard Thibault; Peter Guerra; Mario Talajic; Marc Dubuc
Journal:  Drugs       Date:  2002       Impact factor: 9.546

9.  Pacing in congestive heart failure.

Authors:  Jayne A Morris-Thurgood; Michael P Frenneaux
Journal:  Curr Control Trials Cardiovasc Med       Date:  2000
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.